UroGen Pharma (URGN) Other Non-Current Liabilities (2020 - 2026)
UroGen Pharma's (URGN) quarterly Other Non-Current Liabilities came in at $3.9 million in Q1 2026, up 2.95% YoY from $3.8 million in Q1 2025, and little changed on a QoQ basis from $3.9 million in Q4 2025.
UroGen Pharma (URGN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 7 years of Other Non-Current Liabilities data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 2.95% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 2.95% YoY) and the FY2025 annual result came in at $3.9 million, up 2.95% from the prior year.
- Other Non-Current Liabilities steadied at $3.9 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.9 million in Q4 2025 to a low of $2.8 million in Q1 2022.
- A 5-year average of $3.3 million and a median of $3.2 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities rose 18.69% — and 2025, when it climbed 2.95%.
- Tracing URGN's Other Non-Current Liabilities over 5 years: stood at $3.0 million in 2022, then increased by 5.83% to $3.2 million in 2023, then climbed by 18.69% to $3.8 million in 2024, then increased by 2.95% to $3.9 million in 2025, then changed by 0.0% to $3.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $3.9 million (Q1 2026), $3.9 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.90 Mn |
| Mar 31, 2026 | 3.90 Mn |
| Dec 31, 2025 | 3.90 Mn |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 3.79 Mn |
| Mar 31, 2025 | 3.79 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 3.19 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | 3.19 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 3.02 Mn |
| Jun 30, 2023 | 3.02 Mn |
| Mar 31, 2023 | 3.02 Mn |
| Dec 31, 2022 | 3.02 Mn |
| Sep 30, 2022 | 2.84 Mn |
| Jun 30, 2022 | 2.84 Mn |
| Mar 31, 2022 | 2.84 Mn |
| Dec 31, 2021 | 2.84 Mn |
| Sep 30, 2021 | 2.72 Mn |